Rodríguez-Ballesteros DC, García-Moreno-Mutio SL, Jaimes-Santoyo J, Barbosa-Cobos RE, de Montesinos SA, Beltrán-Ramírez O

Language: Spanish
References: 22
Page: 165-168
PDF size: 120.49 Kb.

ABSTRACT

Breast cancer (BC) is an issue of public health in México due to its frequency and mortality rate. BC is the first cause of death in Mexican female population. The changes in expression of the estrogen receptor alpha (ERα) are important hallmarks that predict the response to endocrine therapy. Absence of this receptor is conditioning for a bad prognosis of BC. DNA methylation is an important regulatory pathway for gene transcription, studies in diverse populations had revealed that its repression is the result of methylation of CpG islands on the promoter of ESR1 gene. To know and explore function and molecular effects of this gene is very important, because if we understand about it, we can propose new mechanisms of the disease and possible diagnostic and prognostic tools.

REFERENCES

1. OMS, Consulta interactiva de datos. Datos y estadísticas. 2008. Disponible en: www.who.int/es. Consultado en 2014.

2. Huicochea S, González P, Tovar I, Olarte M, Vázquez J. Cáncer de mama. Anales de Radiología México 2009; 1: 117-26.

3. INEGI. Consulta interactiva de datos. Estadísticas y mortalidad. 2009. Disponible en: www.inegi.com. Consultado en 2014.

4. Norman R, Lodwick D. Flesh and bones of medical cell biology. 1st Ed. Edinburgh: Elsevier; 2007, p. 132.

5. Giacinti L, Claudio P, Lopez M, Giordano A. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 2006; 11(1): 1-8.

6. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99(3): 247-57.

7. Trasler JM, Trasler DG, Bestor TH, Li E, Ghibu F. DNA methyltransferase in normal and Dnmtn/Dnmtn mouse embryos. Dev Dyn 1996; 206(3): 239-47.

8. Rollins RA, Haghighi F, Edwards JR, Das R, Zhang MQ, Ju J, et al. Large-scale structure of genomic methylation patterns. Genome Res 2006; 16(2): 157-63.

9. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005; 102(30): 10604-9.

10. Sandovici I, Kassovska-Bratinova S, Loredo-Osti JC, Leppert M, Suarez A, Stewart R, et al. Interindividual variability and parent of origin DNA methylation differences at specific human Alu elements. Hum Mol Genet 2005; 14(15): 2135-43.

11. Romulo M, Joseph F. Genome-epigenome interactions in cancer. Hum Mol Genet 2007; 16 spec (R1): R96-R105.

12. Stefansson O, Esteller M. Epigenetic modifications in breast cancer and their role in personalized medicine. Am J Pathol 2013; 183(4): 1052-63.

13. Kissil JL, Feinstein E, Cohen O, Jones PA, Tsai YC, Knowles, et al. DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. Oncogene 1997; 15(4) : 403-7.

14. Akama TO, Okazaki Y, Ito M, Okuizumi H, Konno H, Muramatsu M, et al. Restriction landmark genomic scanning (RLGS-M)- based genome-wide scanning of mouse liver tumors for alterations in DNA methylation status. Cancer Res 1997; 57(15): 3294-9.

15. Roa J, Anabalón L, Tapia O, Martínez J, Villaseca M, Guzmán P, et al. Patrón de metilación génico en el cáncer de mama. Rev Méd Chile 2004; 132: 1059-77.

16. Ramezani F, Salami S, Mir O, Davood M. CpG Island Methylation Profile of Estrogen Receptor Alpha in Iranian Females with Triple Negative or Non-triple Negative Breast Cancer: New Marker of Poor Prognosis. Asian Pac J Cancer Prev 2012; 13(2): 451-7.

17. Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina I, Figimoto SI, et al. Methylation and Inactivation of Estrogen, Progesterone, and Androgen Receptors in Prostate Cancer. J Natl Cancer Inst 2002; 94(5): 384-90.

18. Lopez T, Schiff R. The Dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. Clin Cancer Res 2007; 13(23): 6921-5.

19. Prabhu JS, Wahi K, Korlimarla A, Correa M, Manjunath SN. et al. The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women. Tumor Biol 2012; 33(2): 315-23.

20. Gaudet MM, Campan M, Figueroa JD, Yang XR, Lissowska J, Peplonska B, et al. DNA hypermethylation of ESR1 and PGR in breast cancer: Pathologic and Epidemiologic Associations. Cancer Epidemiol Biomarkers Prev 2009; 18(11): 3036-43.

21. Das PM, Singal R. DNA Methylation and Cancer. J Clinical Oncol 2004; 22(22): 4632-42.

22. Esteller M. Epigenetic changes in cancer. F1000 Biology Reports 2011; 3: 9.